Excipient risk analysis: A new ERA?

Excipient risk management must address the three sources of excipient-related risk; namely, safety, supply chain integrity and technological risk.

Bibliographic Details
Main Author: Brian Carlin
Format: Article
Language:English
Published: International Pharmaceutical Excipients Council 2016-10-01
Series:Journal of Excipients and Food Chemicals
Online Access:https://jefc.scholasticahq.com/article/933-excipient-risk-analysis-a-new-era
_version_ 1797254381734723584
author Brian Carlin
author_facet Brian Carlin
author_sort Brian Carlin
collection DOAJ
description Excipient risk management must address the three sources of excipient-related risk; namely, safety, supply chain integrity and technological risk.
first_indexed 2024-04-24T21:49:03Z
format Article
id doaj.art-7fd616177abd474a935409eba6325448
institution Directory Open Access Journal
issn 2150-2668
language English
last_indexed 2024-04-24T21:49:03Z
publishDate 2016-10-01
publisher International Pharmaceutical Excipients Council
record_format Article
series Journal of Excipients and Food Chemicals
spelling doaj.art-7fd616177abd474a935409eba63254482024-03-20T18:01:35ZengInternational Pharmaceutical Excipients CouncilJournal of Excipients and Food Chemicals2150-26682016-10-0161Excipient risk analysis: A new ERA?Brian CarlinExcipient risk management must address the three sources of excipient-related risk; namely, safety, supply chain integrity and technological risk.https://jefc.scholasticahq.com/article/933-excipient-risk-analysis-a-new-era
spellingShingle Brian Carlin
Excipient risk analysis: A new ERA?
Journal of Excipients and Food Chemicals
title Excipient risk analysis: A new ERA?
title_full Excipient risk analysis: A new ERA?
title_fullStr Excipient risk analysis: A new ERA?
title_full_unstemmed Excipient risk analysis: A new ERA?
title_short Excipient risk analysis: A new ERA?
title_sort excipient risk analysis a new era
url https://jefc.scholasticahq.com/article/933-excipient-risk-analysis-a-new-era
work_keys_str_mv AT briancarlin excipientriskanalysisanewera